Feasibility and Safety of Prehospital Administration of Bivalirudin in Patients With ST-Elevation Myocardial Infarction

American Journal of Cardiology

Volumn 103, Issue 12, 2009, Pages 1635-1640

  Sejersten, Maria ^a   Nielsen, Søren Loumann ^b   Engstrøm, Thomas ^a   Jørgensen, Erik ^a   Clemmensen, Peter ^a  

^a Rigshospitalet   (Denmark)

^b Mobile Emergency Care Unit   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; GLYCERYL TRINITRATE; HEPARIN; HIRULOG; MORPHINE;

ACUTE HEART INFARCTION; ADULT; AGED; AMBULANCE; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD PRESSURE MONITORING; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY MONITORING; EMERGENCY CARE; FEASIBILITY STUDY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; TELEMONITORING; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTICOAGULANTS; ANTITHROMBINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HIRUDINS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PILOT PROJECTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 67649655825     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.02.015     Document Type: Article

References (28)

1. Antman E.M., Hand M., Armstrong P.W., Bates E.R., Green L.A., Halasyamani L.K., Hochman J.S., Krumholz H.M., Lamas G.A., Mullany C.J., et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 Writing Committee. Circulation 117 (2008) 296-329
2. Van de Werf F., Bax J., Betriu A., Blomstrom-Lundqvist C., Crea F., Falk V., Filippatos G., Fox K., Huber K., Kastrati A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 29 (2008) 2909-2945
3. Andersen H.R., Nielsen T.T., Rasmussen K., Thuesen L., Kelbaek H., Thayssen P., Abildgaard U., Pedersen F., Madsen J.K., Grande P., et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349 (2003) 733-742
4. Ellis S.G., Tendera M., de Belder M.A., van Boven A.J., Widimsky P., Janssens L., Andersen H.R., Betriu A., Savonitto S., Adamus J., et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358 (2008) 2205-2217
5. Van't Hof A., Ten Berg J., Heestermans T., Dill T., Funck R., van Werkum W., Dambrink J., Suryapranata H., van Houwelingen G., Ottervanger J., et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 372 (2008) 537-546
6. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. J Am Med Assoc 289 (2003) 853-863
7. Lincoff A.M., Kleiman N.S., Kereiakes D.J., Feit F., Bittl J.A., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. J Am Med Assoc 292 (2004) 696-703
8. Singh S., Molnar J., and Arora R. Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions. J Cardiovascular Pharmacol Ther 12 (2007) 283-291
9. Stone G.W., McLaurin B.T., Cox D.A., Bertrand M.E., Lincoff A.M., Moses J.W., White H.D., Pocock S.J., Ware J.H., Feit F., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
10. Stone G.W., Ware J.H., Bertrand M.E., Lincoff A.M., Moses J.W., Ohman E.M., White H.D., Feit F., Colombo A., McLaurin B.T., et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. J Am Med Assoc 298 (2007) 2497-2506
11. Stone G.W., Witzenbichler B., Guagliumi G., Peruga J.Z., Brodie B.R., Dudek D., Kornowski R., Hartmann F., Gersh B.J., Pocock S.J., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358 (2008) 2218-2230
12. Bittl J.A., Chaitman B.R., Feit F., Kimball W., and Topol E.J. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the bivalirudin angioplasty study. Am Heart J 142 (2001) 952-959
13. Topol E.J., Bonan R., Jewitt D., Sigwart U., Kakkar V.V., Rothman M., de Bono D., Ferguson J., Willerson J.T., Strony J., et al. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation 87 (1993) 1622-1629
14. Stone G.W., Bertrand M., Colombo A., Dangas G., Farkouh M.E., Feit F., Lansky A.J., Lincoff A.M., Mehran R., Moses J.W., et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 148 (2004) 764-775
15. Huikuri H.V., Castellanos A., and Myerburg R.J. Sudden death due to cardiac arrhythmias. N Engl J Med 345 (2001) 1473-1482
16. Braunwald E., Angiolillo D., Bates E., Berger P.B., Bhatt D., Cannon C.P., Furman M.I., Gurbel P., Michelson A.D., Peterson E., et al. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol 31 (2008) I17-I20
17. Braunwald E., Angiolillo D., Bates E., Berger P.B., Bhatt D., Cannon C.P., Furman M.I., Gurbel P., Michelson A.D., Peterson E., et al. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol 31 (2008) I2-I9
18. Lev E.I., Kornowski R., Vaknin-Assa H., Brosh D., Fuchs S., Battler A., and Assali A. Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol 101 (2008) 435-439
19. Reed M.D., and Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy 22 (2002) 105S-111S
20. Yusuf S., Mehta S.R., Chrolavicius S., Afzal R., Pogue J., Granger C.B., Budaj A., Peters R.J., Bassand J.P., Wallentin L., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
21. Moscucci M., Fox K.A., Cannon C.P., Klein W., Lopez-Sendon J., Montalescot G., White K., and Goldberg R.J. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary events (GRACE). Eur Heart J 24 (2003) 1815-1823
22. Wong P., Robinson A., Shaw S., and Rodrigues E. Long term clinical outcome and bleeding complications among hospital survivors with acute coronary syndromes. Postgrad Med J 82 (2006) 224-227
23. Kinnaird T.D., Stabile E., Mintz G.S., Lee C.W., Canos D.A., Gevorkian N., Pinnow E.E., Kent K.M., Pichard A.D., Satler L.F., et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92 (2003) 930-935
24. Stone G.W., White H.D., Ohman E.M., Bertrand M.E., Lincoff A.M., McLaurin B.T., Cox D.A., Pocock S.J., Ware J.H., Feit F., et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369 (2007) 907-919
25. Mehta R.H., Harjai K.J., Cox D., Stone G.W., Brodie B., Boura J., O'Neill W., and Grines C.L. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 42 (2003) 1739-1746
26. Stella J.F., Stella R.E., Iaffaldano R.A., Stella D.J., Erickson K.W., and Bliley III R.C. Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Invasive Cardiol 16 (2004) 451-454
27. Abildstrøm S.Z., Rasmussen S., Kruse M., and Madsen M. Dansk Hjerteregister-Årsberetning. 2nd ed. (2005), Statens Institut for Folkesundhed, Copenhagen
28. Cohen D.J., Lincoff A.M., Lavelle T.A., Chen H.L., Bakhai A., Berezin R.H., Jackman D., Sarembock I.J., and Topol E.J. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 44 (2004) 1792-1800